275 related articles for article (PubMed ID: 7761092)
21. R-Ras is regulated by activators and effectors distinct from those that control Ras function.
Huff SY; Quilliam LA; Cox AD; Der CJ
Oncogene; 1997 Jan; 14(2):133-43. PubMed ID: 9010215
[TBL] [Abstract][Full Text] [Related]
22. Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells.
Huang Y; Rangwala F; Fulkerson PC; Ling B; Reed E; Cox AD; Kamholz J; Ratner N
Oncogene; 2004 Jan; 23(2):368-78. PubMed ID: 14724565
[TBL] [Abstract][Full Text] [Related]
23. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
24. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells.
Mazières J; Tillement V; Allal C; Clanet C; Bobin L; Chen Z; Sebti SM; Favre G; Pradines A
Exp Cell Res; 2005 Apr; 304(2):354-64. PubMed ID: 15748883
[TBL] [Abstract][Full Text] [Related]
25. Disrupting the transforming activity of shrimp ras(Q(61)K) by deleting the CAAX box at the C-terminus.
Huang CF; Chen CH; Chuang NN
J Exp Zool; 2001 Jun; 289(7):441-8. PubMed ID: 11351331
[TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of R-ras3: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution.
Kimmelman A; Tolkacheva T; Lorenzi MV; Osada M; Chan AM
Oncogene; 1997 Nov; 15(22):2675-85. PubMed ID: 9400994
[TBL] [Abstract][Full Text] [Related]
27. Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation.
Graham SM; Cox AD; Drivas G; Rush MG; D'Eustachio P; Der CJ
Mol Cell Biol; 1994 Jun; 14(6):4108-15. PubMed ID: 8196649
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
Adnane J; Bizouarn FA; Chen Z; Ohkanda J; Hamilton AD; Munoz-Antonia T; Sebti SM
Oncogene; 2000 Nov; 19(48):5525-33. PubMed ID: 11114730
[TBL] [Abstract][Full Text] [Related]
29. Critical role of Rho in cell transformation by oncogenic Ras.
Prendergast GC; Khosravi-Far R; Solski PA; Kurzawa H; Lebowitz PF; Der CJ
Oncogene; 1995 Jun; 10(12):2289-96. PubMed ID: 7784077
[TBL] [Abstract][Full Text] [Related]
30. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
[TBL] [Abstract][Full Text] [Related]
31. TC21 causes transformation by Raf-independent signaling pathways.
Graham SM; Vojtek AB; Huff SY; Cox AD; Clark GJ; Cooper JA; Der CJ
Mol Cell Biol; 1996 Nov; 16(11):6132-40. PubMed ID: 8887643
[TBL] [Abstract][Full Text] [Related]
32. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
[TBL] [Abstract][Full Text] [Related]
33. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic Ras-mediated downregulation of Gadd153/CHOP is required for Ras-induced cellular transformation.
Rong R; Montalbano J; Jin W; Zhang J; Garling M; Sheikh MS; Huang Y
Oncogene; 2005 Jul; 24(30):4867-72. PubMed ID: 15870698
[TBL] [Abstract][Full Text] [Related]
35. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
36. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
Prendergast GC; Oliff A
Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
[TBL] [Abstract][Full Text] [Related]
37. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.
Lebowitz PF; Davide JP; Prendergast GC
Mol Cell Biol; 1995 Dec; 15(12):6613-22. PubMed ID: 8524226
[TBL] [Abstract][Full Text] [Related]
38. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
39. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
Shantz LM; Pegg AE
Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
[TBL] [Abstract][Full Text] [Related]
40. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]